Literature DB >> 10613657

The procoagulant state of the VX-2 tumor in rabbit lung in vivo--relative accumulation of fibrinogen, prothrombin, plasminogen, antithrombin and heparin cofactor II within the tumor.

M W Hatton1, B Ross, L Bardossy, S M Southward, M DeReske, M Richardson, M A Blajchman.   

Abstract

During their growth, many malignant solid tumors elicit a hemostatic response in the host. In this report, the fluxes of various rabbit plasma hemostatic proteins into pulmonary VX-2 tumors have been measured in vivo. VX-2 cells were contained within a small rabbit plasma clot which was injected intravenously into rabbits. At 28 d, each rabbit was injected intravenously with two radiolabeled (131I, 125I) proteins selected from fibrinogen, prothrombin, antithrombin-alpha, heparin cofactor II, or plasminogen-I or -II. After allowing the labeled proteins to circulate for 10-200 min, each rabbit was perfused with Krebs-Henseleit solution and the lungs excised. Solid tumors were isolated, weighed and measured for radioactivity content. A mean of 14 tumors/pair of lungs with a mean tumor weight of 0.3 g was obtained. Radioactivity per g of tumor was related to radioactivity/ml of blood at exsanguination for each protein at each time interval. Maximum flux rates were calculated (as pmol/g of tumor/min): Fibrinogen, 65.0; prothrombin, 53.0; antithrombin-alpha, 24.1; HCII, 17.2; plasminogen-II, 5.0; and plasminogen-I, 3.2. Using immunocytochemical staining, fibrin(ogen) was distributed heterogeneously within the VX-2 tumor, appearing largely in the perinodular region and in the necrotic core. From the net fluxes of these proteins, the profile of chronic hemostasis associated with the VX-2 tumor was shown to differ markedly from the hemostatic response that occurs after an acute vascular injury.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10613657

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  2 in total

1.  A total fibrinogen deficiency is compatible with the development of pulmonary fibrosis in mice.

Authors:  V A Ploplis; J Wilberding; L McLennan; Z Liang; I Cornelissen; M E DeFord; E D Rosen; F J Castellino
Journal:  Am J Pathol       Date:  2000-09       Impact factor: 4.307

2.  Antibody-based targeting of alternatively spliced tissue factor: a new approach to impede the primary growth and spread of pancreatic ductal adenocarcinoma.

Authors:  Dusten Unruh; Betül Ünlü; Clayton S Lewis; Xiaoyang Qi; Zhengtao Chu; Robert Sturm; Ryan Keil; Syed A Ahmad; Timofey Sovershaev; Mariette Adam; Patrick Van Dreden; Barry J Woodhams; Divya Ramchandani; Georg F Weber; Janusz W Rak; Alisa S Wolberg; Nigel Mackman; Henri H Versteeg; Vladimir Y Bogdanov
Journal:  Oncotarget       Date:  2016-05-03
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.